COMPANY ANNOUNCEMENT - No. 10-2022 -
BIRKERØD,
Reference is made to company announcement no. 08-2022 of
The following resolutions were passed:
- Attorney-at-law
Nicolai Jung was elected chairman of the general meeting. - The general meeting approved the board’s report on the company’s business for 2021.
- The annual report was approved.
-
It was resolved to transfer the loss for the financial year 2021 of
DKK 17,662,617 to the next year. - The remuneration report was approved by an indicative vote.
Lars Kongsbak andLars Krogsgaard were re-elected as board members. Jørgen Thorball andHenrik Stender resigned. The chairman thanked both members for their service on the board.Patrik Dahlen andValérie Soulier were elected as new board members.-
It was resolved that the annual remuneration fee for the work of the board in 2022 will be fixed at
DKK 150,000 for the chairman andDKK 75,000 for each of the other directors. BDO Statsautoriseret Revisionsaktieselskab was re-elected as auditor for the company.- The proposal for amending Article 2.13.1 was approved.
- The proposal for amending Article 2.3 was approved by a qualified vote.
- The proposal for amending Article 2.3.1 was approved by a qualified vote.
- Nothing was resolved related to this point on the agenda.
The announcement can be found at https://www.virogates.com/investor/announcements
For further information, please contact:
CEO,
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About
The company was founded in 2000. Headquartered in
About suPAR and suPARnostic®
suPAR is a biomarker detected by
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing global demands on health systems and tightening healthcare budgets necessitate efficiency improvements and innovative hospital solutions. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length of stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on
Disclosure regulation
Prospects about the future reflect
Contacts
Jakob Knudsen , CEO, +45 2226 1355, jk@virogates.com
Attachments
- 20220428-Company Announcement 10-AGM resolutions.pdf
© Ritzau Denmark, source